1. Pre-exposure prophylaxis: a useful tool to prevent human immunodeficiency virus infection? 
G. Pialoux, C. Delaugerre, L. Cotte, F. Raffi, E. Cua, J.-M. Molina 
Clinical Microbiology and Infection 
Volume 22, Issue 9, Pages (September 2016)
DOI: /j.cmi
Copyright © 2016 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions

2. Fig. 1
Kaplan–Meier analysis and reduction in the risk of simian/human immunodeficiency virus infection after rectal challenge by daily or intermittent emtricitabine/tenofovir disoproxil fumarate in macaques (from ref. [17]).
Clinical Microbiology and Infection  , DOI: ( /j.cmi )
Copyright © 2016 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions

3. Fig. 2
Summary of the efficacy of oral or topical pre-exposure prophylaxis in clinical trials.
Clinical Microbiology and Infection  , DOI: ( /j.cmi )
Copyright © 2016 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions

4. Fig. 3 Pre-exposure prophylaxis study timeline.
Clinical Microbiology and Infection  , DOI: ( /j.cmi )
Copyright © 2016 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions

5. Fig. 4
Event-driven pre-exposure prophylaxis used in IPERGAY study (ref. [24]).
Clinical Microbiology and Infection  , DOI: ( /j.cmi )
Copyright © 2016 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions